Influence of the Physical Form of Processed Rice Products on the Enzymatic Hydrolysis of Rice Starchin Vitroand on the Postprandial Glucose and Insulin Responses in Patients with Type 2 Diabetes Mellitus

2004 ◽  
Vol 68 (9) ◽  
pp. 1831-1836 ◽  
Author(s):  
Jae Cherl KIM ◽  
Jung-In KIM ◽  
Byoung-Wook KONG ◽  
Min-Jung KANG ◽  
Myo-Jeong KIM ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Enzymatic Hydrolysis ◽  
Postprandial Glucose ◽  
Physical Form ◽  
Insulin Responses ◽  
Hydrolysis Of

scholarly journals A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients

2018 ◽  
Vol 119 (8) ◽  
pp. 910-917 ◽  
Author(s):  
Amirsalar Samkani ◽  
Mads J. Skytte ◽  
Daniel Kandel ◽  
Stine Kjaer ◽  
Arne Astrup ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Gut Hormones ◽  
High Protein Diet ◽  
Postprandial Glucose ◽  
High Protein ◽  
Moderate Reduction ◽  
Simple Substitution

AbstractThe aim of the study was to assess whether a simple substitution of carbohydrate in the conventionally recommended diet with protein and fat would result in a clinically meaningful reduction in postprandial hyperglycaemia in subjects with type 2 diabetes mellitus (T2DM). In all, sixteen subjects with T2DM treated with metformin only, fourteen male, with a median age of 65 (43–70) years, HbA1cof 6·5 % (47 mmol/l) (5·5–8·3 % (37–67 mmol/l)) and a BMI of 30 (sd4·4) kg/m2participated in the randomised, cross-over study. A carbohydrate-reduced high-protein (CRHP) diet was compared with an iso-energetic conventional diabetes (CD) diet. Macronutrient contents of the CRHP/CD diets consisted of 31/54 % energy from carbohydrate, 29/16 % energy from protein and 40/30 % energy from fat, respectively. Each diet was consumed on 2 consecutive days in a randomised order. Postprandial glycaemia, pancreatic and gut hormones, as well as satiety, were evaluated at breakfast and lunch. Compared with the CD diet, the CRHP diet reduced postprandial AUC of glucose by 14 %, insulin by 22 % and glucose-dependent insulinotropic polypeptide by 17 % (allP<0·001), respectively. Correspondingly, glucagon AUC increased by 33 % (P<0·001), cholecystokinin by 24 % (P=0·004) and satiety scores by 7 % (P=0·035), respectively. A moderate reduction in carbohydrate with an increase in fat and protein in the diet, compared with an energy-matched CD diet, greatly reduced postprandial glucose excursions and resulted in increased satiety in patients with well-controlled T2DM.

Abstract 11267: LX4211, a Dual Inhibitor of Sodium-Glucose Cotransporters 1 and 2, Reduces Systolic Blood Pressure in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Renal Impairment

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Pablo Lapuerta ◽  
Paul Strumph ◽  
Philip Banks ◽  
Ikenna Ogbaa ◽  
Brian Zambrowicz ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Renal Impairment ◽  
Systolic Blood Pressure ◽  
Severe Renal Impairment ◽  
Postprandial Glucose ◽  
Dual Inhibitor

Introduction: Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors target only the kidney, and they have reduced efficacy when patients with type 2 diabetes mellitus (T2DM) have renal impairment (RI). LX4211 blocks sodium and glucose absorption in the gastrointestinal tract by inhibition of SGLT1, and it enhances urinary sodium and glucose excretion in the urine through inhibition of SGLT2. The dual SGLT1/2 action of LX4211 was anticipated to reduce systolic blood pressure (SBP) in addition to improving glucose control in the setting of RI. Methods: This analysis explored the effect of LX4211 on SBP in a clinical trial of patients with T2DM and moderate to severe RI. Patients (N=31) were randomly assigned to be treated with LX4211 (400 mg, N=16) or placebo (N=15) qd for 7 consecutive days. Postprandial glucose levels after a standard high glucose meal served as the primary measure of pharmacodynamic activity. Baseline and Day 8 trough SBP measures were each an average of 3 seated assessments. Results: Mean baseline characteristics included age 66.4 years, estimated glomerular filtration rate (eGFR) 43.4 mL/min/1.73 m 2 , and SBP 130.9 mmHg. Postprandial glucose area under the curve (sampled from pre-dose to 4 hours post meal) was reduced from Baseline to Day 7 by 169.3 mg*hr/dL on LX4211 compared to placebo (p=0.003). Day 8 SBP reductions were 11.4 mmHg on LX4211 and 0.0 mmHg on placebo (p=0.045 for difference between groups). Patients with greater RI (eGFR <45 mL/min/1.73 m2) treated with LX4211 (N=6) had a 10.5 mmHg SBP reduction compared to 0.3 mmHg on placebo (N=9). The difference between seated and standing SBP did not change with LX4211 (0.0 mmHg change, Day 8 vs. Baseline). There were no reports of hypotension, hypovolemia, no serious adverse events, and no patient discontinued due to an adverse event. Mild hypoglycemia was reported in 1 LX4211 patient compared to 2 placebo patients. Conclusions: LX4211 may reduce SBP and enhance glycemic control in T2DM patients with moderate to severe RI.

scholarly journals Ambulatory glucose profile in managing hypoglycemia in patients with type 2 diabetes mellitus: a case report

2020 ◽  
Vol 7 (2) ◽  
pp. 340
Author(s):  
B. M. Makkar
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Glycosylated Hemoglobin ◽  
Glucose Monitoring ◽  
Postprandial Glucose ◽  
Glucose Profile ◽  
Glucose Fluctuations

Continuous glucose monitoring (CGM) was done in a 41 years-old female patient with type 2 diabetes mellitus (T2DM) to evaluate the glucose fluctuations, to achieve better glycemic control. The patient presented to the clinic with lethargy, on/off episodes of extreme weakness, sweating, and tingling sensation in the feet (B/L), with leg pains for the past 3 months. She did not have any history of hypertension and cardiovascular disease. On examination, her blood pressure was found to be 120/70 mm Hg. The fasting plasma glucose was 96 mg/dL, postprandial glucose was 160 mg/dL, and glycosylated hemoglobin was 6.8%. The patient was on metformin (500mg)- glimepiride (2mg) combination, once daily, before breakfast, and metformin (500mg) after dinner. Since the symptoms were related to glucose fluctuations and hypoglycemia, the patient was consequently recommended professional CGM to analyze the complete glycemic profile. The profile obtained from Ambulatory Glucose Profile (AGP) revealed glucose fluctuations observed as hypoglycaemia and hyperglycemic episodes. Consequently, the patient’s treatment regimen was changed. The use of glimepiride was discontinued, and the patient was recommended with vildagliptin (50 mg) and metformin combination (1000 mg) bid with meals. This case study indicates that the use of CGM may help in improving our understanding of glycemic patterns and may have a beneficial effect on glycemic control.

scholarly journals Case Report: A Confirmed COVID-19 Patient with Type 2 Diabetes Mellitus

2020 ◽  
Vol 2 (3) ◽  
pp. 144-152
Author(s):  
Annisa Nidya Sitepu ◽  
Santi Syafril
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Sugar ◽  
Rna Virus ◽  
Age Groups ◽  
The Elderly ◽  
Postprandial Glucose ◽  
Single Chain

COVID-19 is caused by a novel coronavirus known as SARS-CoV-2, a single chain RNA virus with a particle size of 120-160 nm. Covid-19 can affect almost all age groups, despite, the elderly and people who have records of chronic disease (co-morbid) have the risk to be affected more often and with worse complications from this disease. Diabetes mellitus (DM) is one of the risk factors for enhancing the severity of COVID-19 infection. A 26 years old man, was referred to the hospital with symptoms of shortness of breath, fever, and cough. The patient has no history of comorbidities, but his father has newly type-2 diabetes mellitus (T2DM). The patient was examined, with ad random blood sugar of 220 mg/dL and a chest radiograph suggesting bronchopneumonia. The patient was then examined for fasting and postprandial glucose, HbA1c, and diagnosed with DM, the patient's throat swab showed a positive COVID-19 result. Patients were then treated with antiviral, antibiotic, regulated insulin, and his blood sugar was monitored. The patient's blood sugar is stable and the patient discharge after 34 days of hospitalization.

Influence of Diabetogenic Factors on Fasting and Postprandial Glucose Levels in Patients with Type 2 Diabetes Mellitus

2019 ◽  
Vol 17 (9) ◽  
pp. 465-471
Author(s):  
Yuan-Tung Chang ◽  
Chung-Ze Wu ◽  
Chang-Hsun Hsieh ◽  
Jin-Biou Chang ◽  
Yao-Jen Liang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Postprandial Glucose ◽  
Glucose Levels
Sign in / Sign up

Export Citation Format

Share Document